UAB Lung Health Center
Welcome,         Profile    Billing    Logout  
 12 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dransfield, Mark
NCT06376994: Multi-Center Clean Air Randomized Controlled Trial in COPD

Recruiting
3
770
US
Air cleaner, Sham air cleaner
JHSPH Center for Clinical Trials, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease (COPD)
09/27
09/28
NCT03085485: The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

Completed
2
40
US
Ivacaftor 150 MG, KALYDECO, Placebo
University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI), Vertex Pharmaceuticals Incorporated
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
09/22
09/22
ATALANTa, NCT03679598: Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Hourglass Jul 2021 - Dec 2021 : From ATALANTA trial for alpha-1 antitrypsin deficiency
Completed
2
63
US
Alvelestat (MPH966), Placebo
University of Alabama at Birmingham, National Institutes of Health (NIH), Mereo BioPharma, National Center for Advancing Translational Sciences (NCATS)
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
11/23
12/23
DEPTH, NCT05382208: Doxycycline for Emphysema in People Living With HIV (The Trial)

Recruiting
2
250
US
Doxycycline, Placebo
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan
Emphysema, HIV
02/27
02/27
ZEVR, NCT04186546: Zephyr Valve Registry

Active, not recruiting
N/A
150
US
Zephyr Valve Procedure, Zephyr Endobronchial Valve, Endobronchial Valve, Bronchoscopic Lung Volume Reduction, BLVR
Pulmonx Corporation
Emphysema
12/24
12/26
DLP-LHC, NCT06177717: Deep Functional Phenotyping of the ALA Lung Health Cohort

Recruiting
N/A
1000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, University of Vermont
Lung Diseases
07/26
07/26
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
SPIROMICS, NCT01969344: Study of COPD Subgroups and Biomarkers

Active, not recruiting
N/A
2981
US
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI), COPD Foundation, Columbia University, Johns Hopkins University, National Jewish Health, Temple University, University of Alabama at Birmingham, University of California, Los Angeles, University of California, San Francisco, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University
COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
12/30
12/30
SOURCE, NCT05033990: SPIROMICS Study of Early COPD Progression

Recruiting
N/A
1000
US
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina, Chapel Hill, Columbia University, Johns Hopkins University, National Jewish Health, University of Alabama at Birmingham, University of California, Los Angeles, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University Health Sciences, Temple University, University of California, San Francisco, COPD Foundation, Mayo Clinic
COPD, Early-Onset
01/25
04/25
NCT04165564: DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Active, not recruiting
N/A
85
US
Institutional standard of care, Biosamples of airway and blood
Boston University, Johnson & Johnson, American College of Radiology Imaging Network
Pulmonary Disease
12/26
12/26
NCT05204888: MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Recruiting
N/A
642
Canada, US
myAirvo3, Pulse oximeter
Temple University, Fisher and Paykel Healthcare
COPD
01/27
03/27
Wells, James
NCT06376994: Multi-Center Clean Air Randomized Controlled Trial in COPD

Recruiting
3
770
US
Air cleaner, Sham air cleaner
JHSPH Center for Clinical Trials, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease (COPD)
09/27
09/28
NCT03843671: Hyperbaric Radiation Sensitization of Head and Neck Cancers

Not yet recruiting
2
400
Canada, US
Hyperbaric oxygen, Hyperbaric chamber
National Baromedical Services, Mayo Clinic, Dartmouth-Hitchcock Medical Center, CISSS de Chaudière-Appalaches, Memorial Hermann Hospital, David Grant U.S. Air Force Medical Center, 59th Medical Wing, Prisma Health Richland Hospital, William Jennings Bryan Dorn VA Medical Center
Squamous Cell Carcinoma of the Head and Neck
12/22
12/24
NCT06505603: PiMZ Longitudinal Cohort (PiMZ Logic)

Not yet recruiting
N/A
80
US
Columbia University, Alpha-1 Foundation
Alpha 1-Antitrypsin Deficiency, Emphysema or COPD
02/29
02/29
A1BC, NCT05297812: Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Active, not recruiting
N/A
286
US
Columbia University, Alpha-1 Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Alpha 1-Antitrypsin Deficiency, Genetic Disease
01/27
01/27
Bhatt, Surya P
RELIANCE, NCT04069312: Roflumilast or Azithromycin to Prevent COPD Exacerbations

Recruiting
4
1250
US
Roflumilast, Daliresp, Azithromycin, Zithromax
Johns Hopkins University, Patient-Centered Outcomes Research Institute, University of Illinois at Chicago
Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
03/26
05/26
INHALE, NCT06135324: Impairments That Affect Correct Inhaler Use in COPD

Recruiting
N/A
500
US
COPD Foundation, Viatris Inc.
COPD
12/24
07/25
AIRFLOW-3, NCT03639051: Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Active, not recruiting
N/A
464
Europe, US
Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care
Nuvaira, Inc.
COPD
10/24
09/28
A1BC, NCT05297812: Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Active, not recruiting
N/A
286
US
Columbia University, Alpha-1 Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Alpha 1-Antitrypsin Deficiency, Genetic Disease
01/27
01/27
NCT05119556: Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease

Recruiting
N/A
768
US
Video Telehealth Pulmonary Rehabilitation
University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease
06/26
08/27
LaFon, David
NCT04164212: Live Attenuated Influenza Vaccine As a Nasal Model for Influenza Infection

Recruiting
4
25
US
Flumist Quadrivalent Nasal Product, live attenuated influenza vaccine
University of Alabama at Birmingham
Influenza
12/25
12/25
Luckhardt
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
Wells, Melessia
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
Dsouza, Kevin G
NCT05656664: Mitigation Efforts in Arsenic Exposure With Folic Acid Supplementation

Enrolling by invitation
N/A
100
US
Folic Acid, Placebo
University of Alabama at Birmingham, National Institute of Environmental Health Sciences (NIEHS)
Arsenic and/or Arsenic Compound Adverse Reaction
06/25
06/25

Download Options